Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) [Phase 3]

View source ↗

Summary

This document reports a Phase 3 clinical trial update for KarXT plus KarX-EC in cognitive impairment associated with Alzheimer's disease, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• KarX-EC
• KarXT (xanomeline-trospium)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Alzheimer's Disease | Phase 3 | Status: RECRUITING